這是一項前瞻性、多中心隨機試驗，於中風險或高風險 NMIBC 患者中比較 cTURBT 聯合 1 年 BCG 治療與 ERBT 聯合 1 年 BCG 治療。
適應症：Bladder Cancer
收案條件
納入條件
- Age 18 years or above
- Fulfil any one of the following three criteria:
- Recurrent bladder tumour
- Multiple bladder tumours
- Any bladder tumour size of \>1cm
排除條件
- EAU low-risk NIMBC as intravesical BCG therapy should not be offered (5)
- EAU very high-risk NMIBC as upfront radical cystectomy should be offered (5)
- Any prior use of intravesical BCG therapy
- Presence or prior history of upper urinary tract malignancy
- Presence of clinically significant cardiovascular disease (History of acute myocardial infarction, presence of uncontrolled angina within 3 months before screening, New York Heart Association Class III or IV congestive heart failure, presence of ventricular arrhythmias, or presence of second-degree or third-degree heart block) (16)
- Presence of GOLD Stage III or IV chronic obstructive pulmonary disease
- ECOG performance status ≥ 2 (Ambulatory and capable of all self-care but unable to carry our any work activities) (18)
- History of bleeding disorder or use of anti-coagulants
- Pregnancy
- Presence of other active malignancy
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。